Catheter Precision, a US-based medical device company, has completed the acquisition of the remaining 80.02 per cent equity interest in Flyte from Creatd, resulting in 100 per cent ownership of the AI-enabled US regional aviation operator.

The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing Catheter Precision as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure and scalable fleet economics.

Flyte operates under FAA 14 CFR Part 135 certification through its wholly owned subsidiary, Ponderosa Air, deploying Cirrus Vision Jets across high-frequency, short-haul regional routes where commercial airline capacity remains constrained or does not exist. The business currently generates revenue through the operation of aircraft equipped with advanced integrated safety systems, including whole-aircraft parachute technology and Safe Return autonomous landing capability.

With full ownership now complete, all Flyte operations, assets and economics are fully consolidated within Catheter Precision, providing direct exposure to operating performance and long-term equity value creation. Going forward, Flyte's financial results will be consolidated into Catheter Precision's financial statements.

With full ownership of Flyte, Catheter Precision: completes a transformative business combination; expands into asset-backed transportation infrastructure; aligns capital, governance and growth strategy under a single structure; and positions shareholders for long-term equity upside through disciplined fleet expansion.

The acquisition reflects Catheter Precision's strategy of selectively deploying capital into operating businesses with tangible assets, scalable infrastructure and clear paths to durable value creation.

“This transaction marks a defining inflection point for Catheter Precision,” says David Jenkins, CEO and chairman of Catheter Precision. “We have transformed from a minority investor into the owner of an operating aviation business with tangible assets, certified infrastructure and immediate revenue. Management believes full ownership of Flyte materially enhances Catheter Precision's long-term valuation profile by contributing consolidated revenues, asset backing and the potential for substantial operating leverage.”

Unlike pre-commercial or speculative aviation concepts, Flyte operates today with: certified aircraft and trained flight crews; established regulatory approvals and operating infrastructure; and active customer demand across multiple premium, high-volume, regional markets.

The Flyte model emphasises capital efficiency, high aircraft utilisation and measured expansion aligned with demand and infrastructure readiness, supporting sustainable growth and long-term value creation rather than speculative deployment.

Flyte operates in many of the same short-haul corridors targeted by future advanced air mobility and electric aircraft developers. By operating today with certified aircraft and established infrastructure, Flyte generates real operating data, route density and customer engagement, while maintaining flexibility to participate in future industry evolution.

This structure allows Catheter Precision to participate in long-term regional air mobility growth without reliance on extended certification timelines, pairing current revenue generation with future strategic optionality.

“Being listed on a national stock exchange and becoming a wholly owned subsidiary of Catheter Precision provides Flyte with aligned governance, capital support and a clear execution framework,” notes Marc Sellouk, CEO and founder of Flyte. “Our focus remains disciplined execution, operating safely, scaling responsibly and building a durable aviation operating platform designed for long-term value creation.”